Completed PHASE1 INTERVENTIONAL 2-arm NCT03032315

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Clinical Trial to Compare the Pharmacokinetics of TAH Tablet(80/10/12.5mg) in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Sponsor: IlDong Pharmaceutical Co Ltd

Conditions Healthy

Interventions Hydrochlorothiazide TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5) TWYNSTA(Telmisartan+Amlodipine besylate)

Updated 6 times since 2017 Last updated: Jan 25, 2017 Started: Oct 1, 2016 Primary completion: Dec 27, 2016 Completion: Dec 27, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03032315, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by IlDong Pharmaceutical Co Ltd, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IlDong Pharmaceutical Co Ltd

Data source: IlDong Pharmaceutical Co Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chonbuk, South Korea